Literature DB >> 9008461

L-arginine prevents xanthoma development and inhibits atherosclerosis in LDL receptor knockout mice.

W Aji1, S Ravalli, M Szabolcs, X C Jiang, R R Sciacca, R E Michler, P J Cannon.   

Abstract

BACKGROUND: The potential antiatherosclerotic actions of NO were investigated in four groups of mice (n = 10 per group) lacking functional LDL receptor genes, an animal model of familial hypercholesterolemia. Group 1 was fed a regular chow diet. Groups 2 through 4 were fed a 1.25% high-cholesterol diet. In addition, group 3 received supplemental L-arginine and group 4 received L-arginine and N omega-nitro-L-arginine (L-NA), an inhibitor of NO synthase (NOS). METHODS AND
RESULTS: Animals were killed at 6 months; aortas were stained with oil red O for planimetry and with antibodies against constitutive and inducible NOSs. Plasma cholesterol was markedly increased in the animals receiving the high-cholesterol diet. Xanthomas appeared in all mice fed the high-cholesterol diet alone but not in those receiving L-arginine. Aortic atherosclerosis was present in all mice on the high-cholesterol diet. The mean atherosclerotic lesion area was reduced significantly (P < .01) in the cholesterol-fed mice given L-arginine compared with those receiving the high-cholesterol diet alone. The mean atherosclerotic lesion area was significantly larger (P < .01) in cholesterol-fed mice receiving L-arginine + L-NA than in those on the high-cholesterol diet alone. Within the atherosclerotic plaques, endothelial cells immunoreacted for endothelial cell NOS; macrophages, foam cells, and smooth muscle cells immunostained strongly for inducible NOS and nitrotyrosine residues.
CONCLUSIONS: The data indicate that L-arginine prevents xanthoma formation and reduces atherosclerosis in LDL receptor knockout mice fed a high-cholesterol diet. The abrogation of the beneficial effects of L-arginine by L-NA suggests that the antiatherosclerotic actions of L-arginine are mediated by NOS. The data suggest that L-arginine may be beneficial in familial hypercholesterolemia.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9008461     DOI: 10.1161/01.cir.95.2.430

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  21 in total

1.  Endothelial dysfunction in atherosclerotic mice: improved relaxation by combined supplementation with L-arginine-tetrahydrobiopterin and enhanced vasoconstriction by endothelin.

Authors:  J Jiang; G Valen; S Tokuno; P Thorén; J Pernow
Journal:  Br J Pharmacol       Date:  2000-12       Impact factor: 8.739

2.  Higher cardiorespiratory fitness attenuates the risk of atherosclerosis associated with ADRB3 Trp64Arg polymorphism.

Authors:  Motoyuki Iemitsu; Shumpei Fujie; Haruka Murakami; Kiyoshi Sanada; Hiroshi Kawano; Yuko Gando; Ryoko Kawakami; Noriko Tanaka; Motohiko Miyachi
Journal:  Eur J Appl Physiol       Date:  2014-03-23       Impact factor: 3.078

3.  Physical training and metabolic supplementation reduce spontaneous atherosclerotic plaque rupture and prolong survival in hypercholesterolemic mice.

Authors:  Claudio Napoli; Sharon Williams-Ignarro; Filomena de Nigris; Lilach O Lerman; Francesco P D'Armiento; Ettore Crimi; Russell E Byrns; Amelia Casamassimi; Alessandro Lanza; Fernando Gombos; Vincenzo Sica; Louis J Ignarro
Journal:  Proc Natl Acad Sci U S A       Date:  2006-06-26       Impact factor: 11.205

4.  Chlamydia pneumoniae infection significantly exacerbates aortic atherosclerosis in an LDLR-/- mouse model within six months.

Authors:  L Liu; H Hu; H Ji; A D Murdin; G N Pierce; G Zhong
Journal:  Mol Cell Biochem       Date:  2000-12       Impact factor: 3.396

5.  Effects of L- and D-arginine on the basal tone of human diseased coronary arteries and their responses to substance P.

Authors:  D Tousoulis; C Tentolouris; T Crake; G Katsimaglis; C Stefanadis; P Toutouzas; G J Davies
Journal:  Heart       Date:  1999-05       Impact factor: 5.994

6.  Vasomotor effects of L- and D-arginine in stenotic atheromatous coronary plaque.

Authors:  D Tousoulis; G J Davies; C Tentolouris; G Goumas; C Stefanadis; P Toutouzas
Journal:  Heart       Date:  2001-09       Impact factor: 5.994

7.  Overexpression of endothelial nitric oxide synthase accelerates atherosclerotic lesion formation in apoE-deficient mice.

Authors:  Masanori Ozaki; Seinosuke Kawashima; Tomoya Yamashita; Tetsuaki Hirase; Masayuki Namiki; Nobutaka Inoue; Ken-ichi Hirata; Hiroyuki Yasui; Hiromu Sakurai; Yuichi Yoshida; Masahiro Masada; Mitsuhiro Yokoyama
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

8.  Endothelin ETA receptor blockade restores NO-mediated endothelial function and inhibits atherosclerosis in apolipoprotein E-deficient mice.

Authors:  M Barton; C C Haudenschild; L V d'Uscio; S Shaw; K Münter; T F Lüscher
Journal:  Proc Natl Acad Sci U S A       Date:  1998-11-24       Impact factor: 11.205

Review 9.  Endothelial nitric oxide (NO) and its pathophysiologic regulation.

Authors:  Anuran Chatterjee; Stephen M Black; John D Catravas
Journal:  Vascul Pharmacol       Date:  2008-07-20       Impact factor: 5.773

Review 10.  Cardiovascular roles of nitric oxide: a review of insights from nitric oxide synthase gene disrupted mice.

Authors:  Victor W T Liu; Paul L Huang
Journal:  Cardiovasc Res       Date:  2008-01       Impact factor: 10.787

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.